2Eagan RT,Frytak S,Creagan ET,et al.Rhase Ⅱstudy of Cyclophosphamide,adramycin,and Cis-Dichlorodiammine platinum(11) by infusion in patients with adenocarcinoma and large cell carcinoma of the lung.Can Trat Rep,1979,63(9-10)1589
21，Grrrn RF, Collins JM, Jenkins JF,et al. Plasma pharmacokinetics of Adriamycin and adriamycinol implications for the desing of in vitro experiments and treatment protocols [J]. Cancer Res, 1983,43:3417
32，Speth PAJ, Linssen PCM, Holderinet RSG,et al. Plasma and cellular adriamycin concentrations in patients nith myeloma treated with ninety-six-hour continuous infusion [J].Clin Pharnacol Therap, 1987,41:661
43，Stallard S, Morrisor JG, George WD,et al. Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy [J]. Cancer Chemother Pharmacol, 1990,25:286.
55， Gasparini G, Toffoli G, Berlanda G,et al. A pharmacological rationale for neoadjurant chemotherapy with adriamycin in locally advanced reast cancer [J]. Anticancer Res, 1990, 10:193
4Lamson DW, Plaza SM. The anticancer effects of Vitamin K [ J ].Altem Med Rev,2003,8(3 ) :303.
5Jakobsen P, Steiness E, Bastholt,et al. Multiple - dose pharmaco- kinetics of epirubicin at four different dose levels: studies in pa- tients with metastatic breast cancer [ J ]. Cancer Chemother Phar- macol, 1991,28:63 - 68.
6孙燕.表阿霉素.中国临床药理学杂志,1985,1(4):283-290.
7Vora J , Boroujerlerdi M.Pharmacokinetic toxicodynamic relationships of adriamycin in rat: prediction of butylated hydroxyanisolemediated reduction in angh racycline ca- rdio toxicity[J]. J Pharm Pharmacol, 1996,48(11) : 1 264.
8Len WS, Karel U, Jiri S, et al.The pharmacokinetics of Po- lylmer-bound adriamycin[J]. Biochem Pharmacol, 1990, 39(5) : 1 125.
